Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Abstract: Methods are provided for the treatment of cancer or neoplastic diseases and the like, by administering 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluoro- benzonitrile (compound of Formula (I)) or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1) to patients in need thereof. Methods are further drawn to administering compositions described herein to patients having neoplastic cells that express RCOR2.

Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

Abstract: The invention is directed to BAHD acyltransferase enzymes, nucleic acids encoding BAHD acyltransferase enzymes, and inhibitory nucleic acids adapted to inhibit the expression and/or translation of BAHD acyltransferase RNA; expression cassettes, plant cells, and plants that have or encode such nucleic acids and enzymes; and methods of making and using such nucleic acids, enzymes, expression cassettes, cells, and plants.

Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

Abstract: The invention is directed to p-coumaroyl-CoA:monolignol transferase enzymes, nucleic acids encoding p-coumaroyl-CoA:monolignol transferase enzymes, and inhibitory nucleic acids adapted to inhibit the expression and/or translation of p-coumaroyl-CoA:monolignol transferase RNA; expression cassettes, plant cells, and plants that have or encode such nucleic acids and enzymes; and methods of making and using such nucleic acids, enzymes, expression cassettes, cells, and plants.

Abstract: The invention relates to feruloyl-CoA:monolignol transferase enzymes and nucleic acids encoding the feruloyl-CoA:monolignol transferase enzymes. The enzymes and/or the nucleic acids enable incorporation of monolignol ferulates into the lignin of plants. The monolignol ferulates include, for example, p-coumaryl ferulate, coniferyl ferulate, and/or sinapyl ferulate.

Abstract: According to examples, a system for generating and delivering enhanced content utilizing remote rendering and data streaming is described. The system may include a processor and a memory storing instructions. The processor, when executing the instructions, may cause the system to transmit a selected engagement content item for transmission to a user device and receive an indication of interest relating to the selected engagement content item. The processor, when executing the instructions, may then select, based on the received indication of interest, an enhanced content item, process the enhanced to content item to generate a stream of content data associated with the enhanced content item and transmit the stream of content data associated with the enhanced content item to the user device.

Abstract: The present application relates generally to a lysine specific demethylase-1 (LSD-1) inhibitor, or a pharmaceutically acceptable salt thereof, and nivolumab, for use in methods for treating small cell lung cancer (SCLC) and/or squamous non-small cell lung cancer (sqNSCLC).

Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Abstract: The present invention relates to a process for forming a fuel pellet, based on using a particular formula for making the fuel pellets. The process for forming a fuel pellet comprising of the following steps: providing a particulate carbonaceous material having a particle size of <1 mm; admixing the particulate carbonaceous material with a polysaccharide or a polyvinyl alcohol binder, and a crosslinker; shaping the so-formed mixture to provide the fuel pellet.

Abstract: An abrasive blast cabinet uses a space frame to support panels defining an enclosed volume. One of the panels defines a view port and access ports. Illumination devices positioned on the one panel adjacent to and/or surrounding the view port illuminate the enclosed volume without significant shadowing, glare or reflections. The illumination devices are captured between a frame and the one panel and are protected from the blast environment by channel members which are covered by a transparent plate overlying the view port.

Abstract: According to examples, a system for providing dynamic digital content may include a processor and a memory storing instructions. The processor, when executing the instructions, may cause the system to receive a plurality of data feeds. The processor may further analyze the data feeds to identify values for parameterized variables. A plurality of deep learning (DL) models can be trained to obtain product attribute data from the data feeds. The processor may then identify rules or triggers based on the values of the parameterized variables. The rules and/or triggers cause the processor to dynamically generate or select digital content and transmit the digital content to user communication devices of selected audience.

Abstract: A computer system for security of components includes at least one processor. For a new version of a component, the processor determines, based on a dataset of release events over time, a historical behavioral analysis of (i) a project that is released with prior versions of the component, and/or (ii) historical committer behavior of a committer that committed the new version of the component, and/or (iii) historical behavior of a publisher of the project. The dataset of release events includes event data collected over time regarding open source project, committers, and repository. The processor determines whether the new version of the component presents an unusual risk profile, based on the historical behavioral analysis. The processor facilitates delayed consumption of the new version of the component in response to determining that the new version of the component presents the unusual risk profile.

Abstract: Provided are methods, uses, and articles of manufacture of combination therapies involving immunotherapies and cell therapies, such as adoptive cell therapy, e.g. a T cell therapy, and the use of an inhibitor of an enhancer of zeste homolog 2 (EZH2), for treating subjects having or suspected of having a cancer, and related methods, uses, and articles of manufacture. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs).

Abstract: Enzymes for depolymerizing lignin. The enzymes include dehydrogenases, ?-etherases, and glutathione lyases. The dehydrogenases can comprise one or more or LigD, LigO, LigN, and LigL. The ?-etherases can comprise one or more of LigE, LigF, LigP, and BaeA. The glutathione lyases can comprise any one or more of LigG and a number of non-stereospecific, optionally recombinant glutathione lyases derived from Sphingobium sp. SYK-6, Novosphingobium aromaticivorans, Escherichia coli, Streptococcus sanguinis, Phanerochaete chrysosporium, and other microorganisms. The enzymes can be combined in compositions and/or used in methods of processing lignin or other aromatic compounds in vitro.